Dr. Eduardo Marban | Executive Director, Smidt Heart Institute @CedarsSinai Views are my own, not institutional policy!
Cedars-Sinai Medical Center
Joined May 2021
- Tweets1.4K
- Following381
- Followers2K
- Likes6.2K
Tune in on Tuesday, Oct 20th at 8 am PDT to hear the latest updates on our work with #exomers
Microsoft Teams meeting
Join: teams.microsoft.com/meet/212…
Meeting ID: 212 993 917 099 964
Passcode: i8iF9Rb7
This week’s #journalclub featured @T_Ikenouchi on modulators of #cardiomyocyte proliferation (yes, there are even more lurking out there), @AleCiulloPhD on cell-cell #mitochondrial transfer in #FreidreichsAtaxia (who’d have thought it happens frequently enough to make a therapeutic difference?), and me discussing a phase 1 trial of an anti-RAGE #siRNA for #asthma (nice template for our own upcoming FIH #exomer trials).
Terrific lab meeting this week by @ke_liaoPhD on the mechanism of #depression, which afflicts one third of patients after a #HeartAttack. Amazing discoveries involving #EVs, circular #RNA and depletion of miRs. We even have a prototype therapeutic candidate! Exciting times…
Late Breaking clinical trial #HOPE-3 OLE shows striking benefits of #deramiocel sustained over two years of therapy, and 76% slowing of #Duchenne myopathy progression in those who crossed over from placebo to deramiocel after one year. Work of ace #DMD trialist Craig McDonald highlighted at the @WorldMuscleSoc meeting in Hiroshima. Trial sponsored by @Capricor based on intellectual property from my team at Cedars-Sinai.
Enjoyed my visit to @dgsomucla and the opportunity to discuss #exomers for #scleroderma, #Duchenne and #arrythmogenic #cardiomyopathy
@TheIbrahimLab @AleCiulloPhD @rrogerslab @EugenioCingolan @soussi_salwa @XMichaelJonesMD
Delighted to have @MarbanLab for an inspiring talk on translating cardiosphere-derived cell biology into RNA therapeutics. Fascinating insights into extracellular vesicles, Y RNA, macrophage reprogramming, tissue repair, and TY1; from discovery to clinical translation. #UCLA
Looking forward to sharing our work on #exomers with friends and colleagues at @dgsomucla next week!
Proud of my two former trainees (the poster, Eugenio, and the speaker, Tetsuo)!!
Fantastic lecture on #AF by Prof Tetsuo Sasano from Tokyo Institute of Science 🇯🇵 @CedarsSinaiMed - from basic mechanisms to improving detection on a #taxiride 🚕 or #hotelbed 🏨 CedarsSinai @APHRSOfficial @HRSonline
Eduardo Marban, MD, PhD retweeted
Suggesting a novel therapy for #SystemicSclerosis: doi.org/10.1172/jci.insight.…
Eduardo Marbán & team @Marbanlab @CedarsSinai report that an orally delivered noncoding RNA (TY1) reduces inflammation and organ fibrosis in models of systemic sclerosis through inhibition of the cGAS/STING axis. The authors employed in vitro and in vivo models and evaluated skin, lung, and heart.
The video shows TY1 treatment in preclinical models of systemic sclerosis.
@AleCiulloPhD @TheIbrahimlab @the_asci
Eduardo Marban, MD, PhD retweeted
Noncoding RNA TY1 reverses fibrosis in systemic sclerosis by attenuating the cGAS/STING pathway @JCI_insight @MarbanLab
insight.jci.org/articles/vie…
Excited to share our latest paper in @JCI_insight, with @XMichaelJonesMD & @TheIbrahimLab : #TY1, an #RNA #exomer drug, reverses the key disease manifestations of #scleroderma in 2 mouse models & in human #SSc cells. The drug works well orally & has unprecedented disease-modifying bioactivity in this horrible disease. Next step: clinical trials!
insight.jci.org/articles/vie…
Eduardo Marban, MD, PhD retweeted
Percutaneous Atrial Delivery of TBX18 Creates a Stable Supraventricular Biological Pacemaker in Porcine Sick Sinus Syndrome | JACC: Clinical Electrophysiology jacc.org/doi/10.1016/j.jacep…
@JACCJournals #JACCEP #Biopacer
#Biopace #CRM #RhythmsAndMore
Lancet paper provides important independent validation of the HOPE-3 trial. Let’s get #deramiocel to all #Duchenne patients in dire need.
We're pleased to share that @TheLancet has published results from Capricor's Phase 3 HOPE-3 trial evaluating Deramiocel in #Duchenne muscular dystrophy.
The independent peer-reviewed publication validates the trial's design, statistical methodology and findings. HOPE-3 met its primary endpoint, with Deramiocel slowing upper limb function decline by 54 percent versus placebo (PUL 2.0, p=0.03) and demonstrating a clinically meaningful cardiac benefit.
Read more here: thelancet.com/journals/lance…
We are grateful to the patients, families, investigators and study teams who made this research possible.
